Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
/ 1659 items
#XY↓
Rocket Scores $180 Million Cash Boost – Extends Runway to 2028 for Heart Gene Therapies
Rocket Pharma sold an FDA voucher for $180M cash, boosting funds without dilution and extending runway to 2028 for heart gene therapies.
Erasca Stock Crashes on Patient Death — But Analysts Call the Selloff Overdone
Erasca stock fell after a patient died in a cancer drug trial. Analysts say it’s likely a rare case, drug still shows promise.
HyBryte Skin Cancer Drug Fails Key Test – Soligenix FLASH2 Trial Halted
Soligenix stopped HyBryte CTCL trial early as it didn’t work well, though it was safe; company will review data and options.
Catalyst Pharmaceuticals Stock Surges on Angelini Pharma Buyout Rumors
Angelini Pharma may buy Catalyst Pharmaceuticals. Talks are early, but news pushed Catalyst’s stock up. No deal is certain yet.
Craig-Hallum Initiates Strong Buy on Spruce Biosciences with $140 Price Target as TA-ERT Advances Toward Approval
Spruce Biosciences has a rare disease drug (TA-ERT) showing strong results, FDA path clear, big sales and upside potential.